Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET
Company Participants
Jessica Serra - Head, IR, Communications & ESG
Mark Foley - CEO
Dustin Sjuts - President
Toby Schilke - CFO
Conference Call Participants
Seamus Fernandez - Guggenheim Partners
Mikaela Franceschina - Barclays
David Amsellem - Piper Sandler
Stacy KU - TD Cowen
Annabel Samimy - Stifel
Uy Ear - Mizuho
Serge Belanger - Needham and Company
Douglas Tsao - H.C. Wainwright
Terence Flynn - Morgan Stanley
Navann Ty - BNP Paribas
Operator
Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. [Operator Instructions]. As a reminder, this call is being recorded today, Wednesday, November 8, 2023.
I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance. Please go ahead.
Jessica Serra
Thank you, operator. Joining us on the call today from Revance are Chief Executive Officer, Mark Foley, President, Dustin Sjuts, and Chief Financial Officer, Toby Schilke. During this conference call, management will make forward-looking statements, including statements related to guidance, positive adjusted EBITDA, adjusted gross margins, operating leverage, blockbuster potential.
The financial impact of OPUL exit, the impact of our pricing strategy and adoption, our competitive market position, our potential value creation, additional therapeutics approvals, plans related to the timing of launch and payer coverage of DAXXIFY for cervical dystonia, international expansion, relationships with providers, our commercial success, injector, consumer and patient preferences and behavior, the efficacy duration and safety of DAXXIFY, the benefits of our products and strategy, our strategic partnership shifts and strategy, timeline, goals and planned operations.
Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause results to be different from these statements can be found in our Risk Factors section of our recent SEC filings.
Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in our earnings release to meet accessible.